Anixa biosciences announces second dose administered to patient in ovarian cancer car-t clinical trial

Patient showed clinical activity after initial treatment, with necrosis, inflammation, and t cell infiltration observed in tumor biopsy from the lowest dose san jose, calif. , oct. 15, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has administered the second dose of its car-t therapy to an individual patient.
CAR Ratings Summary
CAR Quant Ranking